Suppr超能文献

克服骨肉瘤的治疗耐药性:骨肉瘤干细胞的分子机制与治疗靶点概述

Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.

作者信息

Fujiwara Tomohiro, Ozaki Toshifumi

机构信息

Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 7008558, Japan; Department of Intelligent Orthopaedic System, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 7008558, Japan.

Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 7008558, Japan.

出版信息

Stem Cells Int. 2016;2016:2603092. doi: 10.1155/2016/2603092. Epub 2016 Dec 27.

Abstract

Bone sarcomas are heterogeneous malignant tumors that exhibit clinical, histological, and molecular heterogeneity. Recent progress in their multimodal treatment has gradually improved patient prognosis; however, drug resistance and distant metastasis remain unresolved clinical problems. Recent investigations have suggested the existence of cancer stem-like cells (CSCs) in bone sarcomas, which represent a subpopulation of tumor cells with high tumor-forming ability. The hallmarks of CSCs include tumor- and metastasis-forming potential and drug resistance, which are responsible for poor prognoses of bone sarcoma patients. Therefore, elucidation of the molecular mechanisms of CSCs and identification of therapeutic targets could contribute to novel treatment strategies for bone sarcomas and improve patient prognosis. This paper provides an overview of the accumulating knowledge on bone sarcoma stem cells and preclinical analyses to overcome their lethal phenotypes, in addition to a discussion of their potential for novel therapeutics for bone sarcomas.

摘要

骨肉瘤是异质性恶性肿瘤,表现出临床、组织学和分子层面的异质性。其多模式治疗的最新进展已逐渐改善了患者预后;然而,耐药性和远处转移仍是尚未解决的临床问题。最近的研究表明骨肉瘤中存在癌症干细胞样细胞(CSCs),它们代表具有高肿瘤形成能力的肿瘤细胞亚群。CSCs的特征包括肿瘤形成和转移潜能以及耐药性,这些是骨肉瘤患者预后不良的原因。因此,阐明CSCs的分子机制并确定治疗靶点有助于制定骨肉瘤的新治疗策略并改善患者预后。本文概述了关于骨肉瘤干细胞的积累知识以及克服其致死表型的临床前分析,此外还讨论了它们在骨肉瘤新疗法中的潜力。

相似文献

2
Cancer Stem Cells in Soft-Tissue Sarcomas.
Cells. 2020 Jun 10;9(6):1449. doi: 10.3390/cells9061449.
3
Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.
Cancer Drug Resist. 2022 Feb 16;5(1):184-198. doi: 10.20517/cdr.2021.130. eCollection 2022.
4
Targeting sarcomas: therapeutic targets and their rational.
Semin Diagn Pathol. 2008 Nov;25(4):304-16. doi: 10.1053/j.semdp.2008.07.005.
5
Do stem-like cells play a role in drug resistance of sarcomas?
Expert Rev Anticancer Ther. 2010 Feb;10(2):261-70. doi: 10.1586/era.09.184.
6
Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
BMC Med Genomics. 2019 Jan 31;12(Suppl 1):23. doi: 10.1186/s12920-018-0456-5.
7
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas.
J Clin Med. 2021 Jun 14;10(12):2621. doi: 10.3390/jcm10122621.
8
[Molecular biology of sarcoma and therapeutic choices].
Bull Cancer. 2015 Jan;102(1):6-16. doi: 10.1016/j.bulcan.2014.12.005. Epub 2015 Jan 13.
9
MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.
Front Mol Biosci. 2015 Jun 17;2:31. doi: 10.3389/fmolb.2015.00031. eCollection 2015.
10
Soft Tissue Sarcoma Cancer Stem Cells: An Overview.
Front Oncol. 2018 Oct 26;8:475. doi: 10.3389/fonc.2018.00475. eCollection 2018.

引用本文的文献

1
T cell receptor signaling pathway subgroups and construction of a novel prognostic model in osteosarcoma.
Heliyon. 2024 Dec 12;11(1):e41191. doi: 10.1016/j.heliyon.2024.e41191. eCollection 2025 Jan 15.
2
Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma.
Front Oncol. 2023 Jun 19;13:1219211. doi: 10.3389/fonc.2023.1219211. eCollection 2023.
4
Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations.
Drug Deliv. 2022 Dec;29(1):1631-1647. doi: 10.1080/10717544.2022.2075983.
5
Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review.
Cancers (Basel). 2021 Aug 23;13(16):4229. doi: 10.3390/cancers13164229.
7
Molecular Biology of Osteosarcoma.
Cancers (Basel). 2020 Jul 31;12(8):2130. doi: 10.3390/cancers12082130.
8
Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Mol Oncol. 2020 May;14(5):1101-1117. doi: 10.1002/1878-0261.12655. Epub 2020 Mar 13.
9
Soft Tissue Sarcoma Cancer Stem Cells: An Overview.
Front Oncol. 2018 Oct 26;8:475. doi: 10.3389/fonc.2018.00475. eCollection 2018.

本文引用的文献

1
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal.
Front Oncol. 2016 May 10;6:115. doi: 10.3389/fonc.2016.00115. eCollection 2016.
2
3
Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.
J Cell Physiol. 2016 Apr;231(4):876-86. doi: 10.1002/jcp.25179. Epub 2015 Sep 9.
4
Endosialin‑expressing bone sarcoma stem‑like cells are highly tumor‑initiating and invasive.
Mol Med Rep. 2015 Oct;12(4):5665-70. doi: 10.3892/mmr.2015.4218. Epub 2015 Aug 12.
7
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models.
Oncotarget. 2015 Sep 15;6(27):23662-70. doi: 10.18632/oncotarget.4282.
9
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
J Med Chem. 2015 May 14;58(9):4073-9. doi: 10.1021/acs.jmedchem.5b00126. Epub 2015 Apr 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验